益盛药业(002566) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 226,591,334.39, down 11.44% year-on-year[7] - Net profit attributable to shareholders was CNY 13,847,363.90, a decrease of 5.56% compared to the same period last year[7] - Basic earnings per share were CNY 0.0418, a decrease of 5.64% compared to the same period last year[7] - The weighted average return on net assets was 0.76%, a decrease of 0.32% year-on-year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 13,646,819.49, down 2.57% year-on-year[7] - The company reported a net profit increase of 20.70% for the year-to-date period, totaling CNY 53,129,794.87[7] - Total operating revenue for the third quarter was ¥226,591,334.39, a decrease of 11.43% from ¥255,858,096.99 in the previous period[37] - Net profit for the third quarter was ¥16,584,006.69, down 17.73% from ¥20,158,479.27 in the same period last year[39] - The company reported an increase in other income to ¥1,183,793.92 from ¥919,301.03[39] - The company’s total profit for the quarter was ¥19,872,213.20, down from ¥32,388,257.89 in the previous year[39] - Total operating revenue for the current period is $750.06 million, a slight increase from $747.50 million in the previous period, representing a growth of approximately 0.21%[46] - Net profit for the current period reached $68.36 million, up from $59.40 million in the previous period, indicating a growth of approximately 15.4%[47] - The total profit for the current period is $80.89 million, a decrease from $81.51 million in the previous period, indicating a decline of about 0.76%[47] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,607,357,800.15, a decrease of 1.74% compared to the end of the previous year[7] - The company's cash and cash equivalents decreased from ¥80,585,720.38 at the beginning of the period to ¥63,185,732.05 at the end of the period, representing a decline of approximately 21.5%[30] - Total current assets decreased from ¥2,117,334,641.37 to ¥2,078,456,335.19, a decline of about 1.8%[30] - Total assets decreased from ¥2,653,485,977.68 to ¥2,607,357,800.15, representing a reduction of approximately 1.7%[31] - Total liabilities decreased from ¥756,402,227.66 to ¥658,466,185.16, a decline of about 12.9%[32] - The company's total equity increased from ¥1,897,083,750.02 to ¥1,948,891,614.99, reflecting a growth of approximately 2.7%[32] - Short-term borrowings decreased from ¥540,000,000.00 to ¥490,000,000.00, a reduction of about 9.3%[32] - The company's total equity increased to ¥1,864,145,391.36 from ¥1,846,831,133.99[39] Cash Flow - Net cash flow from operating activities was CNY 28,009,259.45, down 32.91% year-on-year[7] - Operating cash flow decreased by 39.73% to ¥92,381,953.78 due to reduced cash inflow from sales of goods and services[17] - The net cash flow from operating activities was ¥102,656,014.49, a decrease of 34% compared to ¥155,724,193.71 in the previous period[57] - Total cash inflow from financing activities was ¥500,598,000.00, down from ¥532,669,968.71 in the previous period[58] - The net cash flow from investing activities was -¥42,529,268.35, compared to -¥33,131,318.41 in the previous period, indicating increased investment outflows[57] - The ending balance of cash and cash equivalents was ¥46,289,927.33, down from ¥53,620,510.20 in the previous period[58] - Cash received from sales of goods and services was ¥634,690,963.41, slightly up from ¥631,092,685.55 in the previous period[57] - The company reported a cash outflow of ¥33,961,665.72 for dividend distribution and interest payments, compared to ¥21,563,958.36 in the previous period[58] - The company had a net cash decrease of ¥13,236,919.58 from financing activities, compared to a decrease of ¥6,301,114.35 in the previous period[58] - The company’s cash and cash equivalents decreased by ¥13,236,919.58 during the period, reflecting ongoing financial challenges[58] Shareholder Information - The total number of shareholders at the end of the reporting period was 24,249[11] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[11] - The company plans to reduce the shareholding of certain shareholders to ensure accurate information disclosure[13] Research and Development - Research and development expenses increased to ¥6,455,227.73, up 89.96% from ¥3,405,138.79[37] - Research and development expenses rose to $15.59 million from $14.64 million, marking an increase of approximately 6.5%[46] Other Financial Activities - The company reported no non-operating fund occupation by controlling shareholders during the reporting period[24] - There were no entrusted financial management activities during the reporting period[25] - The company has completed the use of all funds raised from its initial public offering, and all related accounts have been canceled[18] - The company expects a decrease in financial expenses due to a reduction in short-term borrowings[22] - The company reported an 81.39% decrease in interest income to -¥262,612.41 due to reduced interest from raised funds[17] - The company received a loan of ¥10,000,000 for the transformation project of Zhenyuan Capsule, which was accounted for as long-term borrowings[18]